C87977 Activators
Pramel29, belonging to the PRAME family, is forecasted to play a crucial role in ubiquitin ligase-substrate adaptor activity, primarily operating within the Cul2-RING ubiquitin ligase complex. Predicted to be active in the cytoplasm, its functionality aligns with cellular processes regulating protein turnover and degradation. The orthologous relationships with several human genes suggest a level of conservation in functional pathways across species. Understanding the mechanisms governing Pramel29's activation requires an exploration of intricate signaling cascades and cellular processes associated with its predicted functions. Potential activators of Pramel29 can be categorized into those directly impacting its ubiquitin ligase-substrate adaptor activity and those indirectly influencing associated signaling pathways. Inhibitors such as MLN4924 and Pevonedistat, targeting NEDD8-activating enzyme, may disrupt the Cul2-RING ubiquitin ligase complex, potentially stabilizing Pramel29 and preventing its degradation. Modulation of gene expression through BET bromodomain inhibitors like JQ1 or p300/CBP HAT inhibitors like C646 may indirectly affect Pramel29 by altering the chromatin landscape and influencing its transcriptional regulation. Additionally, inhibitors like AZD5363 targeting AKT kinase or SB216763 inhibiting GSK-3 may impact Pramel29 indirectly through the modulation of associated signaling pathways.
The orchestration of Pramel29 activation involves a delicate balance between post-translational modifications, protein-protein interactions, and transcriptional regulation. The interplay of these factors creates a sophisticated regulatory network, where chemicals acting on various nodes can influence the activation status of Pramel29. As our understanding of these regulatory mechanisms evolves, Pramel29 stands as a key player in cellular protein homeostasis, offering insights into the intricate molecular processes that govern its activation and functionality.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Proteasome inhibitor affecting protein degradation. Inhibits proteasome activity, potentially stabilizing Pramel29 by preventing its degradation through the ubiquitin-proteasome system. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $226.00 $846.00 | 1 | |
BET bromodomain inhibitor modulating gene expression. May indirectly influence Pramel29 by altering the chromatin landscape through inhibition of BET bromodomains, impacting the transcriptional regulation of associated genes. | ||||||
Amlexanox | 68302-57-8 | sc-217630 | 10 mg | $160.00 | 2 | |
IKKε/TBK1 inhibitor modulating NF-κB signaling. Inhibits IKKε/TBK1, potentially affecting NF-κB activation. Pramel29, active in the cytoplasm, may be influenced by NF-κB signaling pathways. | ||||||
C646 | 328968-36-1 | sc-364452 sc-364452A | 10 mg 50 mg | $260.00 $925.00 | 5 | |
p300/CBP HAT inhibitor affecting gene transcription. Inhibits p300/CBP HAT, potentially altering the acetylation status of histones. Pramel29's predicted ubiquitin ligase-substrate adaptor activity might be indirectly affected through changes in transcription. | ||||||
(–)-Nutlin-3 | 675576-98-4 | sc-222086 sc-222086A | 1 mg 5 mg | $120.00 $215.00 | 2 | |
MDM2 inhibitor modulating p53 pathway. Inhibits MDM2, stabilizing p53. Pramel29, orthologous to several human genes including PRAMEF1, may be indirectly regulated by the p53 pathway through molecules like Nutlin-3. | ||||||
PI-103 | 371935-74-9 | sc-203193 sc-203193A | 1 mg 5 mg | $32.00 $128.00 | 3 | |
PI3-kinase/mTOR dual inhibitor affecting signaling pathways. Inhibits PI3-kinase and mTOR, potentially influencing Pramel29 through modulation of the PI3K/AKT pathway, to which it is predicted to be associated. | ||||||
SB-216763 | 280744-09-4 | sc-200646 sc-200646A | 1 mg 5 mg | $70.00 $198.00 | 18 | |
GSK-3 inhibitor affecting Wnt/β-catenin signaling. Inhibits GSK-3, potentially affecting Wnt/β-catenin pathways. Pramel29, orthologous to human genes linked to Wnt signaling, may be indirectly influenced through modulation of this pathway. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
HDAC inhibitor affecting histone acetylation. Inhibits HDACs, potentially altering histone acetylation. Pramel29's activation might be influenced by changes in the acetylation status of histones, impacting its transcriptional regulation. | ||||||
THZ1 | 1604810-83-4 | sc-507542 | 1 mg | $95.00 | ||
CDK7 inhibitor affecting transcription. Inhibits CDK7, potentially impacting RNA polymerase II-mediated transcription. Pramel29, predicted to enable ubiquitin ligase-substrate adaptor activity, may be indirectly affected through changes in transcription. | ||||||
AZD5363 | 1143532-39-1 | sc-503190 | 5 mg | $309.00 | ||
AKT kinase inhibitor influencing intracellular signaling. Inhibits AKT kinase, potentially impacting Pramel29 through modulation of the AKT signaling pathway, with which it is predicted to be associated. | ||||||